Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

Relmada Therapeutics, Inc. (Nasdaq: RLMD) provided a corporate update and preliminary financial results for Q3 2023. The company is advancing its Phase 3 clinical development plan for REL-1017 as an adjunctive treatment for major depressive disorder. Recent preclinical data showed promising results for a modified-release psilocybin program. The company also announced upcoming milestones and financial results for Q3 2023.

Positive

• Advancing Phase 3 clinical development plan for REL-1017 for major depressive disorder.
• Promising preclinical data for a modified-release psilocybin program.
• Upcoming anticipated milestones for Phase 1 and Phase 2a trials.
• Significant decrease in research and development expenses for Q3 2023 compared to Q3 2022.
• Net loss decreased for Q3 2023 compared to Q3 2022.

Negative

• None.

CORAL GABLES, Fla., Nov. 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2023. The Company will host a conference call today, Wednesday, November 8, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

"We continue to advance our Phase 3 clinical development plan for REL-1017 as an adjunctive treatment for major depressive disorder (MDD)," said Sergio Traversa, Relmada's Chief Executive Officer. "Enrollment in the ongoing Reliance II (study 302) is progressing as planned and it remains on track to be completed in the in the first half of 2024.  The initial patients have been enrolled into Relight, the new Phase 3 study (study 304), and we continue to anticipate the completion of this trial in the second half of next year. Additionally, we are encouraged by the recently announced efficacy and safety data from the one year, open-label safety study, Reliance-OLS (study 310), which showed rapid and sustained improvement in MADRS score with REL-1017 in both de novo patients and the full analysis set."

"We also recently presented new compelling preclinical data demonstrating the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease (MASLD)," continued Mr. Traversa. "Based on these promising results, we intend to commence a single-ascending dose Phase 1 trial in obese patients with steatotic liver disease in early 2024 to define the pharmacokinetic, safety, and tolerability profile of our modified-release psilocybin formulation in this population, followed by a Phase 2a trial in the same patient population to establish clinical proof-of-concept. Importantly, there are currently no approved drugs for MASLD, and these initial pre-clinical data support the therapeutic potential of non-psychedelic/low dose psilocybin."

Recent Corporate Highlights

• Enrollment is ongoing in Reliance II (study 302) and Relight (study 304), two sister pivotal Phase 3 trials of REL-1017 for the adjunctive treatment of MDD.
  
  
• Announced results from recently completed Reliance-OLS (study 310), a long-term, open-label study of REL-1017 in MDD.
  
  
• Rapid and sustained improvements in MADRS score were observed with REL-1017 in both de novo patient and the full analysis sets.
  
  
• Announced new preclinical data from novel modified-release psilocybin program to be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2023.
  
  
  • Data demonstrated the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease (MASLD).
    
    
• Data presented from REL-1017 and psilocybin programs at the 36^th European College of Neuropsychopharmacology (ECNP) Congress.

Upcoming Anticipated Milestones

• Commence a Phase 1 trial in obese patients with steatotic liver disease in early 2024 to define the pharmacokinetic, safety and tolerability profile of the Company's modified-release psilocybin formulation, followed by a Phase 2a trial to establish clinical proof-of-concept.
  
  
• Complete enrollment of Reliance II, which is planned to enroll approximately 300 patients, in the first half of 2024.
  
  
• Complete enrollment of Relight (study 304), which is planned to enroll approximately 300 patients, in the second half of 2024.

Third Quarter 2023 Financial Results

• Research and development expense for the three months ended September 30, 2023, totaled $10.5 million, compared to $30.5 million for the three months ended September 30, 2022. The decrease was primarily associated with the completion of the Reliance I and Reliance III clinical studies in late 2022.
  
  
• General and administrative expense for the three months ended September 30, 2023, totaled $12.2 million, compared to $8.2 million for the three months ended September 30, 2022. The increase was primarily driven by an increase in stock-based compensation.
  
  
• Net cash used in operating activities for the three months ended September 30, 2023 totaled $11.6 million, compared to $26.9 million for the three months ended September 30, 2022.
  
  
• Net loss for the three months ended September 30, 2023, was $22.0 million, or $0.73 per basic and diluted share, compared with a net loss of $39.4 million, or $1.31 per basic and diluted share, for the three months ended September 30, 2022.

Nine Months Ended September 30, 2023 Financial Results

• Research and development expense for the nine months ended September 30, 2023, totaled $40.1 million, compared to $86.5 million for the nine months ended September 30, 2022. The decrease was primarily driven by a decrease in a study costs associated with the completion of Reliance I and III in late 2022.
  
  
• General and administrative expense for the nine months ended September 30, 2023, totaled $36.8 million, compared to $36.1 million for the nine months ended September 30, 2022. The increase was primarily driven by an increase in stock-based compensation.
  
  
• Net cash used in operating activities for the nine months ended September 30, 2023 totaled $41.4 million, compared to $67.9 million for the three months ended September 30, 2022.
  
  
• Net loss for the nine months ended September 30, 2023 and 2022 was $73.6 million and $119.1 million, respectively. The Company had a net loss of $2.45 and $4.04 per share for the nine months ended September 30, 2023 and 2022, respectively.
  
  
• As of September 30, 2023, the Company had cash, cash equivalents, and short-term investments of approximately $106.3 million, compared to cash, cash equivalents, and short-term investments of approximately $148.3 million at December 31, 2022.

Conference Call and Webcast Details

Wednesday, November 8^th at 4:30 PM ET

Toll Free:	888-886-7786
International:	416-764-8658
Conference ID:	54664628
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1636783&tp_key=a6209aa189

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). The ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Relmada is also developing a novel non-psychedelic/low dose psilocybin for the treatment of metabolic indications. Learn more at www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, failure of the psilocybin program to advance to later stages of development, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:

Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com 

Media Inquiries:

Corporate Communications
media@relmada.com 

Relmada Therapeutics, Inc.
Condensed Consolidated Balance Sheets
		As of
		September 30,				As of
		2023 (Unaudited)				December 31, 2022
Assets
Current assets:
Cash and cash equivalents		$	6,698,599			$	5,395,905
Short-term investments			99,568,502				142,926,781
Other receivables			-				512,432
Prepaid expenses			2,834,037				4,035,186
Total current assets			109,101,138				152,870,304
Other assets			47,715				34,875
Total assets		$	109,148,853			$	152,905,179
Commitments and Contingencies (See Note 6)
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable		$	2,856,752			$	5,261,936
Accrued expenses			5,565,466				7,206,941
Total current liabilities			8,422,218				12,468,877
Stockholders' Equity:
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares      authorized, none issued and outstanding			-				-
Common stock, $0.001 par value, 150,000,000 shares authorized, 30,099,203      shares issued and outstanding			30,099				30,099
Additional paid-in capital			636,434,059				602,517,138
Accumulated deficit			(535,737,523)				(462,110,935)
Total stockholders' equity			100,726,635				140,436,302
Total liabilities and stockholders' equity		$	109,148,853			$	152,905,179

 

Relmada Therapeutics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
		Three months ended								Nine months ended
		September 30,								September 30,
		2023				2022				2023				2022
Operating expenses:
Research and development		$	10,454,072			$	30,529,108			$	40,055,287			$	86,454,632
General and administrative			12,238,566				8,208,053				36,817,686				36,092,024
Total operating expenses			22,692,638				38,737,161				76,872,973				122,546,656
Loss from operations			(22,692,638)				(38,737,161)				(76,872,973)				(122,546,656)
Other (expenses) income:
Gain on settlement of fees			-				-				-				6,351,606
Interest/investment income, net			1,321,441				827,614				3,892,478				1,544,898
Realized loss on short-term investments			(51,714)				(561,648)				(718,422)				(552,171)
Unrealized (loss) gain on short-term investments			(579,147)				(947,512)				72,329				(3,897,135)
Total other (expense) income – net			690,580				(681,546)				3,246,385				3,447,198
Net loss		$	(22,002,058)			$	(39,418,707)			$	(73,626,588)			$	(119,099,458)
Loss per common share – basic and diluted		$	(0.73)			$	(1.31)			$	(2.45)			$	(4.04)
Weighted average number of common shares      outstanding – basic and diluted			30,099,203				30,063,735				30,099,203				29,470,198

 

Relmada Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)
		Nine months ended September 30, 2023
		Common Stock								Additional Paid-in				Accumulated
		Shares				Par Value				Capital				Deficit				Total
Balance – December 31, 2022			30,099,203			$	30,099			$	602,517,138			$	(462,110,935)			$	140,436,302
Stock-based compensation			-				-				11,354,466				-				11,354,466
Net loss			-				-				-				(26,321,576)				(26,321,576)
Balance – March 31, 2023			30,099,203				30,099				613,871,604				(488,432,511)				125,469,192
Stock-based compensation			-				-				11,169,517				-				11,169,517
Net loss			-				-				-				(25,302,954)				(25,302,954)
Balance – June 30, 2023			30,099,203			$	30,099			$	625,041,121			$	(513,735,465)			$	111,335,755
Stock-based compensation			-				-				11,392,938				-				11,392,938
Net loss			-				-				-				(22,002,058)				(22,002,058)
Balance – September 30, 2023			30,099,203				30,099				636,434,059				(535,737,523)				100,726,635
		Nine months ended September 30, 2022
		Common Stock								Additional Paid-in				Accumulated
		Shares				Par Value				Capital				Deficit				Total
Balance – December 31, 2021			27,740,147			$	27,740			$	513,304,258			$	(305,067,112)			$	208,264,886
Stock-based compensation			-				-				11,930,681				-				11,930,681
ATM offering, net			1,609,343				1,610				29,581,932				-				29,583,542
Warrant exercised for cash			33,334				33				299,973				-				300,006
Options exercised for cash			20,000				20				64,780				-				64,800
Net loss			-				-				-				(39,745,783)				(39,745,783)
Balance – March 31, 2022			29,402,824				29,403				555,181,624				(344,812,895)				210,398,132
Stock-based compensation			-				-				12,295,016				-				12,295,016
Warrant exercised for cash			91,058				91				595,259				-				595,350
Options exercised for cash			45,812				46				352,698				-				352,744
ATM offering, net of offering costs			484,900				485				13,144,572				-				13,145,057
Net loss			-				-				-				(39,934,968)				(39,934,968)
Balance – June 30, 2022			30,024,594				30,025				581,569,169				(384,747,863)				196,851,331
Stock-based compensation			-				-				8,343,139				-				8,343,139
Warrant exercised for cash			51,527				51				332,865				-				332,916
Options exercised for cash			17,886				18				286,158				-				286,176
Share exchange – Pre-funded warrants, net      of fees			(1,452,016)				(1,452)				(48,548)				-				(50,000)
Net loss			-				-				-				(39,418,707)				(39,418,707)
Balance – September 30, 2022			28,641,991			$	28,642			$	590,482,783			$	(424,166,570)			$	166,344,855

 

Relmada Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
		Nine months ended
		September 30,
		2023				2022
Cash flows from operating activities
Net loss		$	(73,626,588)			$	(119,099,458)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation			33,916,921				32,568,836
Realized loss on short-term investments			718,422				552,171
Unrealized (gain) loss on short-term investments			(72,329)				3,897,135
Change in operating assets and liabilities:
Lease payment receivable			-				86,377
Other receivable			512,432				-
Prepaid expenses and other assets			1,188,309				8,359,994
Accounts payable			(2,405,184)				(766,661)
Accrued expenses			(1,641,475)				6,482,889
Net cash used in operating activities			(41,409,492)				(67,918,717)
Cash flows from investing activities
Purchase of short-term investments			(57,151,963)				(38,993,173)
Sale of short-term investments			99,864,149				60,382,229
Net cash provided by investing activities			42,712,186				21,389,056
Cash flows from financing activities
Payment of fees for warrants issued for common stock			-				(50,000)
Proceeds from issuance of common stock – net			-				42,728,599
Proceeds from options exercised for common stock			-				703,720
Proceeds from warrants exercised for common stock			-				1,228,272
Net cash provided by financing activities			-				44,610,591
Net increase /(decrease) in cash and cash equivalents			1,302,694				(1,919,070)
Cash and cash equivalents at beginning of the period			5,395,905				44,443,439
Cash and cash equivalents at end of the period		$	6,698,599				42,524,369
Supplemental disclosure of cash flow information:
Non-cash investing and financing activities:
Share exchange for Pre-funded warrants		$	-			$	1,452

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-provides-corporate-update-and-reports-third-quarter-2023-financial-results-301982239.html

SOURCE Relmada Therapeutics, Inc.

FAQ

What are the recent corporate highlights for Relmada Therapeutics, Inc. (Nasdaq: RLMD)?

Enrollment in ongoing pivotal Phase 3 trials for REL-1017, announced results from a long-term study of REL-1017, and presented new preclinical data at a conference.

What are the upcoming anticipated milestones for Relmada Therapeutics, Inc. (Nasdaq: RLMD)?

Commencing Phase 1 and Phase 2a trials for a modified-release psilocybin program, and completing enrollment for two Phase 3 trials.

What are the financial results for Q3 2023 for Relmada Therapeutics, Inc. (Nasdaq: RLMD)?

Decrease in research and development expenses, increase in general and administrative expenses, and a decrease in net loss compared to Q3 2022.